Brought to you by 
Celladon uses V-Kardia's device to deliver its gene therapy
01 Jul 2005
Executive Summary
V-Kardia Pty. Ltd. (cardiovascular device company spun out from the Baker Research Institute this past January) has agreed to develop its V-Focus device to percutaneously deliver Celladon's (cardiovascular therapeutics) congestive heart failure (CHF) gene therapy.
Deal Industry
- Medical Devices
-
Pharmaceuticals
- Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Celladon uses V-Kardia's device to deliver its gene therapy
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice